Current Report Filing (8-k)
September 19 2019 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 17, 2019
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
|
SNSS
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On September 17, 2019, the Board of Directors (the Board) of Sunesis
Pharmaceuticals, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Nicole Onetto to the Board, effective immediately, as a Class I director whose term will
expire at the Companys 2021 annual meeting of stockholders. Effective, September 17, 2019, Ms. Onetto has also been appointed to the Compensation Committee of the Board. The Board has determined that Ms. Onetto is
independent as contemplated by the Nasdaq Stock Market and other governing laws and applicable regulations, including Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the Exchange Act).
There is no arrangement or understanding between Ms. Onetto and the Company or any other person pursuant to which she was elected as a director, and
there is no family relationship between Ms. Onetto and any of the Companys other directors or executive officers. The Company is not aware of any transaction between the Company and Ms. Onetto that would require disclosure under Item
404(a) of Regulation S-K.
Ms. Onetto is expected to receive compensation for service as a director in
accordance with the Companys non-employee director compensation policy (Policy), including annual cash retainer and an annual equity grant. Pursuant to Policy, in connection with her election, she
will receive a non-statutory stock option to purchase 90,000 shares of the Companys Common Stock (the Initial Option) under the Companys 2011 Equity Incentive Plan to be effective on
September 30, 2019 (the Grant Date). The Initial Option will have a maximum term of ten years measured from the Grant Date, and will vest and be exercisable monthly over a two-year period,
provided Ms. Onetto continues to provide services to the Company through each vesting date. In connection with this election, the Company also entered into the Companys standard form of indemnification agreement with Ms. Onetto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
|
Dated: September 19, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ William P. Quinn
|
|
|
|
|
|
|
William P. Quinn
|
|
|
|
|
|
|
Chief Financial Officer, Senior Vice President, Finance and Corporate Development
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024